Cargando…
Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis
Neither lowering of blood lipid levels nor treatment with statins definitively improves renal outcomes. Ezetimibe, a non-statin antilipidemic agent, is known to not only decrease blood lipid levels but also reduce inflammatory response and activate autophagy. We evaluated the effect of adding ezetim...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141215/ https://www.ncbi.nlm.nih.gov/pubmed/32183405 http://dx.doi.org/10.3390/jcm9030798 |
_version_ | 1783519148066734080 |
---|---|
author | Bae, Jaehyun Hong, Namki Lee, Byung-Wan Kang, Eun Seok Cha, Bong-Soo Lee, Yong-ho |
author_facet | Bae, Jaehyun Hong, Namki Lee, Byung-Wan Kang, Eun Seok Cha, Bong-Soo Lee, Yong-ho |
author_sort | Bae, Jaehyun |
collection | PubMed |
description | Neither lowering of blood lipid levels nor treatment with statins definitively improves renal outcomes. Ezetimibe, a non-statin antilipidemic agent, is known to not only decrease blood lipid levels but also reduce inflammatory response and activate autophagy. We evaluated the effect of adding ezetimibe to a statin on renal outcome compared with statin monotherapy by analyzing longitudinal data of 4537 patients treated with simvastatin 20 mg plus ezetimibe 10 mg (S + E) or simvastatin 20 mg alone (S) for more than 180 days. A propensity-score-based process was used to match baseline characteristics, medical history, and estimated glomerular filtration rate (eGFR) between S + E and S groups. Changes in serum creatinine and incidence of renal events, defined as doubling of serum creatinine to ≥1.5 mg/dL or occurrence of end-stage renal disease after the first day of treatment initiation, were compared between the groups. Among 3104 well-matched patients with a median follow-up of 4.2 years, the S + E group showed a significantly lower risk of renal events than the S group (hazard ratio 0.58; 95% CI 0.35-0.95, P = 0.032). In addition, the S + E group tended to preserve renal function compared with the S group throughout follow-up, as assessed by serum creatinine changes (P-values for time–group interactions <0.001). These data support the beneficial effects on renal function when combining ezetimibe with a statin. |
format | Online Article Text |
id | pubmed-7141215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71412152020-04-10 Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis Bae, Jaehyun Hong, Namki Lee, Byung-Wan Kang, Eun Seok Cha, Bong-Soo Lee, Yong-ho J Clin Med Article Neither lowering of blood lipid levels nor treatment with statins definitively improves renal outcomes. Ezetimibe, a non-statin antilipidemic agent, is known to not only decrease blood lipid levels but also reduce inflammatory response and activate autophagy. We evaluated the effect of adding ezetimibe to a statin on renal outcome compared with statin monotherapy by analyzing longitudinal data of 4537 patients treated with simvastatin 20 mg plus ezetimibe 10 mg (S + E) or simvastatin 20 mg alone (S) for more than 180 days. A propensity-score-based process was used to match baseline characteristics, medical history, and estimated glomerular filtration rate (eGFR) between S + E and S groups. Changes in serum creatinine and incidence of renal events, defined as doubling of serum creatinine to ≥1.5 mg/dL or occurrence of end-stage renal disease after the first day of treatment initiation, were compared between the groups. Among 3104 well-matched patients with a median follow-up of 4.2 years, the S + E group showed a significantly lower risk of renal events than the S group (hazard ratio 0.58; 95% CI 0.35-0.95, P = 0.032). In addition, the S + E group tended to preserve renal function compared with the S group throughout follow-up, as assessed by serum creatinine changes (P-values for time–group interactions <0.001). These data support the beneficial effects on renal function when combining ezetimibe with a statin. MDPI 2020-03-15 /pmc/articles/PMC7141215/ /pubmed/32183405 http://dx.doi.org/10.3390/jcm9030798 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bae, Jaehyun Hong, Namki Lee, Byung-Wan Kang, Eun Seok Cha, Bong-Soo Lee, Yong-ho Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis |
title | Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis |
title_full | Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis |
title_fullStr | Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis |
title_full_unstemmed | Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis |
title_short | Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis |
title_sort | comparison of renal effects of ezetimibe–statin combination versus statin monotherapy: a propensity-score-matched analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141215/ https://www.ncbi.nlm.nih.gov/pubmed/32183405 http://dx.doi.org/10.3390/jcm9030798 |
work_keys_str_mv | AT baejaehyun comparisonofrenaleffectsofezetimibestatincombinationversusstatinmonotherapyapropensityscorematchedanalysis AT hongnamki comparisonofrenaleffectsofezetimibestatincombinationversusstatinmonotherapyapropensityscorematchedanalysis AT leebyungwan comparisonofrenaleffectsofezetimibestatincombinationversusstatinmonotherapyapropensityscorematchedanalysis AT kangeunseok comparisonofrenaleffectsofezetimibestatincombinationversusstatinmonotherapyapropensityscorematchedanalysis AT chabongsoo comparisonofrenaleffectsofezetimibestatincombinationversusstatinmonotherapyapropensityscorematchedanalysis AT leeyongho comparisonofrenaleffectsofezetimibestatincombinationversusstatinmonotherapyapropensityscorematchedanalysis |